Peripartum Cardiomyopathy

Overview

Peripartum cardiomyopathy (PPCM) is an idiopathic dilated cardiomyopathy presenting in the final month of pregnancy or within 5 months postpartum (Pearson 2000 Working Group definition) in the absence of prior heart disease and in the absence of any identifiable cause of heart failure. The heart dilates and ejection fraction falls below 45%, causing heart failure symptoms in a previously healthy young woman. PPCM is one of the most important causes of maternal mortality in the modern era.

Despite its severity, PPCM is frequently misdiagnosed as normal pregnancy-related breathlessness. Dyspnea during pregnancy is ubiquitous, but orthopnea in a pregnant woman is NOT normal and should immediately trigger an echocardiogram. Delays in diagnosis worsen outcomes and increase the risk of irreversible ventricular remodeling, thromboembolic complications, and sudden death.

Incidence varies widely by population: approximately 1:1,000–3,000 live births globally; in Nigeria and Haiti approximately 1:100–1:300; Japan among the lowest reported rates; the United States approximately 1:2,500. Rates appear to be increasing, most likely reflecting improved detection and reporting rather than a true rise in incidence.

Back to Table of Contents

Epidemiology and Risk Factors

PPCM does not occur at random — multiple demographic, obstetric, and systemic risk factors have been consistently identified across large registries:

• Older maternal age (>30 years): increasing risk with advancing age at delivery.
• Multiparity (3 or more pregnancies): cumulative cardiovascular demands of repeated pregnancies.
• Twin or multiple gestation: 2–3 times increased risk; markedly elevated hemodynamic demands on the heart.
• Preeclampsia and gestational hypertension: the most consistently identified risk factor; up to 45% of PPCM patients have concomitant preeclampsia. Both share a pathophysiology of endothelial dysfunction and anti-angiogenic signaling.
• African American ethnicity: 5–6 times higher incidence than white women in the United States; significantly worse outcomes including lower recovery rates and higher mortality. Both genetic predisposition and socioeconomic barriers to early diagnosis contribute.
• Cocaine or methamphetamine use: direct cardiotoxicity plus intense vasoconstriction compound hemodynamic stress.
• Selenium deficiency: implicated in endemic cases in rural Haiti and parts of sub-Saharan Africa; selenium is essential for glutathione peroxidase activity, which protects myocytes against oxidative stress.
• Malnutrition and poverty: in endemic regions, nutritional deficiencies compound peripartum cardiovascular vulnerability.
• Prior PPCM: 20–30% risk of recurrence with any subsequent pregnancy, especially if left ventricular function never fully normalized after the index episode.

Women with multiple risk factors — particularly African American ethnicity, preeclampsia, and advanced maternal age — carry the highest absolute risk and warrant early echocardiographic evaluation at any hint of disproportionate dyspnea or fluid retention.

Back to Table of Contents

Pathophysiology — Prolactin, Angiogenic Imbalance, and Genetics

PPCM is not simply dilated cardiomyopathy that happens to occur during pregnancy. A specific pathophysiological mechanism distinct from other cardiomyopathies has been identified, centered on the prolactin hypothesis, with overlapping contributions from angiogenic imbalance and genetic susceptibility.

The Prolactin Hypothesis

The prolactin hypothesis was developed primarily by Hilfiker-Kleiner, Sliwa, and Fett and has become the dominant pathophysiological framework for PPCM:

1. Oxidative stress in the peripartum heart — generated by the metabolic demands of pregnancy, breastfeeding, sleep deprivation, and hemodynamic overload — upregulates Cathepsin D, a lysosomal protease, within cardiomyocytes.
2. Cathepsin D cleaves full-length 23 kDa prolactin into a 16 kDa anti-angiogenic prolactin fragment.
3. This 16 kDa fragment exerts direct cardiac toxicity by: (a) inhibiting cardiomyocyte proliferation and survival; (b) inducing cardiomyocyte apoptosis; (c) impairing the cardiac microvasculature through its anti-angiogenic activity, reducing capillary density and producing ischemic myocardial injury; and (d) acting in a paracrine manner to amplify myocardial damage.
4. Prolactin is markedly elevated throughout pregnancy and especially during breastfeeding, providing abundant substrate for 16 kDa fragment generation.
5. The therapeutic implication is direct: bromocriptine, a dopamine agonist that suppresses prolactin secretion, should block 16 kDa fragment generation and protect the myocardium.

Angiogenic Imbalance and sFlt-1

The placenta releases anti-angiogenic sFlt-1 (soluble fms-like tyrosine kinase-1), which sequesters vascular endothelial growth factor (VEGF) and impairs cardiac microvasculature. This mechanism is also central to preeclampsia pathophysiology, explaining the strong epidemiological association between PPCM and preeclampsia — the two conditions share a common anti-angiogenic underpinning. Sliwa and colleagues demonstrated elevated sFlt-1 in PPCM patients, with levels correlating with disease severity.

Supporting Evidence for the Prolactin Hypothesis

• Knockout of STAT3 (a signal transducer activated downstream of prolactin) in mice produces a spontaneous PPCM-like syndrome, providing mechanistic validation.
• The BOARD Trial (Sliwa 2010): bromocriptine added to standard therapy produced significantly better LV recovery versus standard therapy alone.
• Case series from South Africa, Haiti, and Germany confirm high recovery rates with bromocriptine even in severe PPCM.
• The German PPCM Registry confirms the real-world benefit of prolactin blockade.

Back to Table of Contents

Genetic Basis — TTN and Other Variants

An identifiable pathogenic genetic variant is found in 20–25% of PPCM patients — a rate comparable to familial dilated cardiomyopathy, suggesting that PPCM represents a genetically susceptible heart unmasked by the hemodynamic challenge of pregnancy:

• Titin (TTN) truncating variants (TTNtv): the most common genetic finding in PPCM, present in 10–15% of cases. TTN encodes the giant sarcomeric protein titin, which functions as a molecular spring within the sarcomere. TTNtv impair sarcomere integrity and reduce myocardial resilience to the volumetric and pressure demands of pregnancy. The same variants are found in familial DCM.
• DSP (desmoplakin), FLNC (filamin C), SCN5A (cardiac sodium channel), LMNA (lamin A/C): other DCM-linked genes identified in PPCM patients.
• MYH7, TNNT2, TNNI3: sarcomere genes; less commonly implicated in PPCM than in hypertrophic cardiomyopathy.

Clinical Implications of Genetic Testing

Genetic testing is now recommended in PPCM by both the European Society of Cardiology and recent American guidelines. Key implications include:

• LMNA mutations: carry a higher risk of dangerous arrhythmias and sudden cardiac death, supporting earlier ICD implantation even if EF partially recovers.
• TTNtv: associated with better LVAD bridge-to-recovery outcomes; may predict a more favorable recovery trajectory with appropriate medical support.
• Family cascade screening: first-degree relatives of a PPCM patient with a pathogenic TTN, LMNA, or DSP variant should be evaluated by a cardiomyopathy genetics clinic, particularly daughters who may face their own PPCM risk in future pregnancies.

Back to Table of Contents

Clinical Presentation and Diagnosis

Onset Timing

• Postpartum onset: approximately 45% of cases, occurring within 5 months after delivery with most cases in the first 3 months.
• Antepartum onset (last month of pregnancy): approximately 40%.
• Earlier antepartum presentation (before the last month): approximately 15% — atypical; other diagnoses should be actively considered.

Symptoms

Symptoms mirror those of dilated cardiomyopathy and heart failure but arise in a context where many overlap with normal pregnancy:

• Dyspnea on exertion progressing to dyspnea at rest
• Orthopnea and paroxysmal nocturnal dyspnea (PND): the most clinically important symptoms — orthopnea is NOT a normal feature of pregnancy and must always trigger echocardiographic evaluation
• Profound fatigue from reduced cardiac output
• Lower extremity edema — also common in normal pregnancy, contributing to diagnostic delay
• Palpitations from atrial fibrillation, ventricular tachycardia, or frequent premature ventricular contractions
• Right-sided heart failure symptoms: hepatomegaly, jugular venous distension, ascites in biventricular failure
• Thromboembolic events: LV thrombus occurs in 5–17%; pulmonary embolism and stroke are recognized complications due to the combination of severely reduced EF and pregnancy-associated hypercoagulability

Physical Examination

Tachycardia; laterally displaced apical impulse reflecting LV dilation; S3 gallop; mitral regurgitation murmur from annular dilation; bibasilar pulmonary crackles; elevated jugular venous pressure; and pitting edema of the lower extremities and ankles.

Diagnostic Criteria

Diagnosis is clinical, echocardiographic, and exclusionary. All three conditions must be satisfied:

1. New onset heart failure in the last month of pregnancy or within 5 months postpartum
2. No identifiable cause: not valvular, not congenital, not ischemic coronary disease, not previously known cardiomyopathy
3. LV systolic dysfunction: EF <45% on echocardiography (often severely reduced to 20–35% at presentation in acute cases)

Back to Table of Contents

Echocardiography and Cardiac Imaging

Echocardiogram — First-Line and Essential

Transthoracic echocardiography is the cornerstone of diagnosis and follow-up in PPCM. Key findings include:

• LV EF <45% (often severely reduced, 20–35% in acute presentation)
• LV dilation — may be less prominent than in chronic DCM if the presentation is early and acute
• Four-chamber dilation in severe biventricular failure
• LV thrombus in 5–17% — careful examination of the LV apex is essential at every evaluation
• Mitral and tricuspid regurgitation from annular dilation
• Pulmonary artery pressure elevation in biventricular failure

LV EF at presentation and at 6 months post-diagnosis is the single most important prognostic marker in PPCM.

Cardiac MRI

Cardiac MRI is indicated when echocardiographic windows are suboptimal or the diagnosis is uncertain:

• Provides more accurate EF quantification than echocardiography
• Late gadolinium enhancement (LGE) patterns:
  • Mid-wall enhancement: idiopathic DCM / PPCM pattern (myocardial fibrosis)
  • Subepicardial enhancement: myocarditis pattern (distinguishes from viral myocarditis)
  • Subendocardial or transmural enhancement: ischemic pattern (prompts coronary evaluation)
• Safe in pregnancy; gadolinium should be avoided antepartum unless essential and used at lowest dose postpartum when breastfeeding

Biomarkers

BNP and NT-proBNP are markedly elevated in PPCM, correlating with disease severity and falling with effective treatment. Serial measurements are valuable to track therapeutic response. Troponin elevation reflects myocardial injury and often correlates with LGE extent on MRI. CRP may reflect the inflammatory component of PPCM pathophysiology.

Coronary Assessment

Spontaneous coronary artery dissection (SCAD) is a peripartum-specific cause of myocardial infarction that can mimic PPCM in a young woman presenting with chest pain and heart failure. SCAD must be excluded with CT coronary angiography or invasive coronary angiography, and importantly treated conservatively (PCI worsens dissection propagation in most cases). Standard coronary artery disease is uncommon at this age but possible in the setting of metabolic syndrome or severe preeclampsia-related vascular injury.

Holter Monitoring

Arrhythmias — atrial fibrillation, nonsustained ventricular tachycardia, and frequent PVCs — are common in PPCM. Holter monitoring is essential before ICD decision-making and should be obtained in any patient with palpitations or syncope.

Back to Table of Contents

Standard Heart Failure Treatment (Antepartum)

During pregnancy, teratogenic medications must be avoided. Management focuses on pregnancy-safe agents that reduce hemodynamic burden and prevent complications:

Beta-Blockers (First-Line Antepartum)

• Carvedilol (preferred): combined alpha + beta blockade provides antiadrenergic and antioxidant properties particularly relevant to PPCM pathophysiology; start at 3.125 mg twice daily and titrate
• Metoprolol succinate (beta-1 selective; well-studied in pregnancy): acceptable alternative
• Avoid atenolol: associated with fetal intrauterine growth restriction
• Target resting heart rate below 80 beats per minute; titrate slowly

Diuretics

• Furosemide (loop diuretic): IV for acute decompensated heart failure; oral for maintenance congestion management
• Avoid hypovolemia — fetal placental circulation depends on adequate maternal intravascular volume
• Avoid high-dose diuretics antepartum; use the lowest effective dose

Hydralazine + Nitrates (Afterload Reduction)

• Hydralazine (direct arteriolar vasodilator) + isosorbide dinitrate (venodilator, reduces preload) substitute for ACE inhibitors during pregnancy
• ACE inhibitors and ARBs are absolutely contraindicated in pregnancy — they cause fetal renal agenesis, oligohydramnios, and skull hypoplasia in the second and third trimesters; a single course of ACEi/ARB during pregnancy can cause lethal fetal renal dysgenesis
• The hydralazine + nitrate combination is less potent than ACEi/ARB but is the safest available afterload reduction strategy

Digoxin

Safe in pregnancy. Provides modest positive inotropy and rate control in atrial fibrillation. Limited contemporary use in sinus rhythm given availability of superior agents postpartum, but useful for refractory heart failure or rate control antepartum.

Anticoagulation (Antepartum)

• Low molecular weight heparin (LMWH) — enoxaparin: subcutaneous, does not cross the placenta, safe for the fetus
• Therapeutic anticoagulation is recommended when EF <30% or LV thrombus is identified — the combination of severely reduced EF and pregnancy-associated hypercoagulability creates extreme thromboembolism risk
• Avoid warfarin in the first trimester (warfarin embryopathy) and near delivery (maternal and fetal hemorrhage risk); if used in the second trimester (e.g., mechanical heart valve), use with full recognition of fetal risk

Delivery Planning

Vaginal delivery is generally preferred in stable PPCM — cardiac output perturbations with vaginal delivery are more predictable than with cesarean section under general anesthesia. Epidural analgesia reduces pain-related catecholamine surges and is beneficial in cardiac patients. Assisted delivery (forceps or vacuum) should be planned if prolonged pushing is hemodynamically contraindicated. Oxytocin should be given as a slow infusion, not a bolus; ergometrine is contraindicated due to severe vasoconstriction. Hemodynamic monitoring with arterial line — and pulmonary artery catheter in very severe cases — guides real-time management.

Back to Table of Contents

Standard Heart Failure Treatment (Postpartum)

After delivery, the full guideline-directed medical therapy (GDMT) arsenal for heart failure with reduced ejection fraction (HFrEF) becomes available. The goal is maximal medical therapy to maximize the probability of LV recovery:

ACE Inhibitors and ARBs

Enalapril or lisinopril are the backbone of HFrEF therapy. Low doses of enalapril during breastfeeding appear safe (minimal milk transfer). Titrate to target doses as tolerated, monitoring creatinine and potassium closely.

Sacubitril/Valsartan (ARNi)

The angiotensin receptor-neprilysin inhibitor (ARNi) sacubitril/valsartan is superior to ACE inhibitor alone for reducing HFrEF mortality (PARADIGM-HF trial). Data from the IPAC registry and retrospective studies support use in PPCM postpartum. Because sacubitril/valsartan is teratogenic, it should be started only after delivery and ideally after breastfeeding is discontinued or after a risk-benefit discussion with the patient. It replaces the ACEi or ARB when added to improve EF.

SGLT2 Inhibitors

Dapagliflozin and empagliflozin carry Class 1A recommendation in HFrEF GDMT based on DAPA-HF and EMPEROR-Reduced trials. Safety during breastfeeding is unknown; they are excreted in breast milk in animal models. A frank discussion with the patient regarding the decision to use SGLT2 inhibitors versus continuation of breastfeeding is required.

Mineralocorticoid Receptor Antagonists (MRA)

Spironolactone or eplerenone reduce HFrEF mortality and should be added as part of complete GDMT. Spironolactone has weak anti-androgenic effects and is generally avoided during breastfeeding due to theoretical concerns for breastfed male infants; use postpartum after breastfeeding cessation.

Beta-Blockers (Continued)

Continue carvedilol or metoprolol succinate started antepartum; titrate to guideline target doses over weeks to months as blood pressure and heart rate allow. Do not uptitrate rapidly in the setting of active decompensation.

Anticoagulation (Postpartum)

Switch from LMWH to warfarin postpartum (target INR 2–3) if EF remains below 30% or LV thrombus persists. Anticoagulation can be discontinued when EF has recovered to above 40–45% and thrombus has resolved. Direct oral anticoagulants (DOACs) are not recommended during breastfeeding due to inadequate safety data.

Back to Table of Contents

Bromocriptine — The Prolactin Hypothesis

Bromocriptine is a dopamine D2 receptor agonist that suppresses prolactin secretion from the anterior pituitary. By blocking prolactin, bromocriptine prevents the generation of the cardiotoxic 16 kDa prolactin fragment by Cathepsin D, protecting the myocardium from prolactin-mediated anti-angiogenic and pro-apoptotic injury.

The BOARD Trial (Sliwa et al., Circulation 2010)

The landmark BOARD Trial enrolled South African PPCM patients (n=20) in a randomized design comparing standard heart failure therapy versus standard therapy plus bromocriptine (2.5 mg once daily for 8 weeks). The bromocriptine group achieved significantly higher LVEF recovery (58% vs 36% at 6 months), fewer deaths, and a higher proportion of patients recovering to EF above 50%. This was the first prospective evidence establishing bromocriptine as a PPCM-specific treatment. Critics note the small sample size and that the South African population may not fully generalize to other settings.

Subsequent Evidence

• The German PPCM Registry confirmed that bromocriptine use is associated with significantly better LV recovery in real-world clinical practice.
• An extended bromocriptine trial compared short (2.5 mg once daily for 2 weeks) versus long (2.5 mg twice daily for 2 weeks followed by 2.5 mg once daily for 6 weeks) courses; the long course was non-inferior with similar LV recovery. The short course may be preferred in less severe PPCM.
• Data from Nigeria, Haiti, and Germany collectively support prolactin blockade as a meaningful PPCM-specific treatment.
• The 2019 ESC PPCM Position Statement issued a Class IIa, Level B recommendation for bromocriptine.

Practical Use

• Dosing: 2.5 mg twice daily for 2 weeks, then 2.5 mg once daily for 6 weeks (or shorter course in milder PPCM)
• Mandatory anticoagulation with bromocriptine: bromocriptine increases thrombotic risk through uncertain mechanisms; LMWH thromboprophylaxis is mandatory while bromocriptine is prescribed
• Suppression of breastfeeding: bromocriptine inhibits lactation; patients must be clearly counseled that choosing bromocriptine means stopping breastfeeding. This is a significant and personal decision that should be discussed respectfully and thoughtfully, not simply prescribed
• Use is not yet universal — some centers reserve bromocriptine for severe PPCM (EF <25%) or rapid deterioration; others treat all PPCM; no single standard of care has been established outside of European guidelines

Back to Table of Contents

Advanced Therapies and Device Management

Wearable Cardioverter-Defibrillator (LifeVest)

Many PPCM patients present with an EF below 35% — the standard threshold for permanent ICD implantation. However, PPCM has a high recovery rate (approximately 50% of patients recover to normal EF). Implanting a permanent ICD in the acute phase is premature and exposes patients who will recover to an unnecessary device. The LifeVest wearable cardioverter-defibrillator bridges this gap: it provides continuous protection against sudden cardiac death for 3–6 months while recovery is awaited. If EF has not recovered above 35% at 6 months, a permanent ICD is then implanted. This strategy uniquely distinguishes PPCM management from other cardiomyopathy contexts where ICD implantation typically follows immediately upon meeting criteria.

Cardiac Resynchronization Therapy (CRT)

If QRS prolongation (left bundle branch block morphology, QRS duration above 150 ms) persists at 3–6 months in the setting of EF below 35%, cardiac resynchronization therapy with defibrillation capability (CRT-D) is indicated. CRT improves LV mechanical synchrony and can augment EF recovery in PPCM just as in other HFrEF with LBBB.

Left Ventricular Assist Device (LVAD)

LVAD implantation is indicated for cardiogenic shock or rapidly deteriorating PPCM failing maximal medical therapy. PPCM has a notably higher bridge-to-recovery rate compared to other DCM causes — especially in patients with TTN truncating variants — and some patients can successfully undergo LVAD explantation after sufficient cardiac recovery. For patients without recovery, LVAD serves as a bridge to cardiac transplantation.

Cardiac Transplantation

Cardiac transplantation is required in 1–5% of PPCM patients who do not recover LV function despite LVAD support and maximal medical therapy after 6–12 months. Post-transplant outcomes in PPCM are comparable to other DCM etiologies.

Endomyocardial Biopsy

Endomyocardial biopsy is rarely needed but should be considered when the diagnosis is uncertain — specifically to exclude giant cell myocarditis, which requires immunosuppressive therapy and has a far worse prognosis than PPCM if untreated. Giant cell myocarditis can present identically to PPCM in the peripartum period.

Acute Decompensated PPCM

ICU-level management for cardiogenic shock includes vasopressors (norepinephrine plus vasopressin for refractory hypotension; avoid epinephrine which increases cardiogenic shock mortality), inodilators (dobutamine for low-output state), intra-aortic balloon pump (IABP), percutaneous ventricular assist devices (Impella), and venoarterial extracorporeal membrane oxygenation (VA-ECMO) for the most refractory cases as a bridge to LVAD or transplantation.

Back to Table of Contents

Subsequent Pregnancy Counseling

Counseling women with a history of PPCM about future pregnancies is one of the most critical and emotionally complex conversations in cardiovascular medicine. The risk of recurrence is real regardless of apparent recovery, and the stakes are high.

Risk Stratification

• Prior PPCM with current normal EF (EF ≥55%): recurrence risk approximately 20%; some patients tolerate a subsequent pregnancy without recurrence; careful preconception counseling, high-risk obstetrics co-management, and cardiology oversight throughout pregnancy are essential
• Prior PPCM with persistent reduced EF (<55%): subsequent pregnancy is high risk and is generally discouraged; recurrence risk up to 50% with LV decompensation; risk of maternal death is significant; both the 2019 ESC Position Statement and AHA guidelines recommend advising against further pregnancy in this setting
• If a patient chooses to proceed despite counseling: high-risk obstetric and cardiology co-management throughout pregnancy is mandatory, with early and frequent echocardiographic monitoring beginning in the first trimester

Breastfeeding and PPCM

Elevated prolactin during breastfeeding theoretically sustains the generation of the cardiotoxic 16 kDa prolactin fragment. If bromocriptine is prescribed, breastfeeding must cease — bromocriptine suppresses lactation as part of its mechanism. If bromocriptine is not used, breastfeeding may continue, but the theoretical cardiac risk should be discussed with the patient and the clinical course monitored closely. The decision must be individualized based on the patient's values and the clinical trajectory of LV recovery.

Genetic Counseling

Women with PPCM who carry a pathogenic variant — particularly TTN, LMNA, or DSP — should be referred to a cardiomyopathy genetics clinic for formal counseling. Daughters of PPCM patients with TTN truncating variants face elevated PPCM risk in their own future pregnancies and should be aware of this before planning families.

Back to Table of Contents

Prognosis

Recovery Rates

• Full recovery (EF normalization to ≥55%): approximately 50% of patients within 6–12 months
• Partial recovery (EF improves but remains below 55%): approximately 35%
• No recovery or deterioration: approximately 15%
• Mortality: 3–5% in the first year in high-resource settings; 15–30% in sub-Saharan Africa where diagnosis is delayed and advanced supportive care is unavailable

Predictors of Poor Prognosis

• African American ethnicity: 5–6 times worse outcomes versus white women in United States cohorts
• Low EF at presentation (<30%): one of the strongest predictor of incomplete recovery
• EF remaining below 30% at 6 months: unlikely to recover without advanced device therapy or transplantation
• Concomitant preeclampsia: associated with worse outcomes in some cohorts, though others report that preeclampsia-associated PPCM recovers more completely — data remain mixed
• LMNA mutation: increased arrhythmic sudden cardiac death risk requiring early ICD even after partial EF recovery
• Twin pregnancy: tends to produce more severe initial presentation due to amplified hemodynamic demands

Long-Term Follow-Up

Echocardiography at 6 months is the critical decision point for ICD implantation, transplant listing, and determination of LVAD candidacy. Even after apparent full recovery, annual echocardiography for at least 5 years is recommended because late deterioration of LV function has been documented. Cardiology follow-up should continue for life, with family planning discussions integrated into every cardiology visit. The 6-month echo is also the appropriate time to re-evaluate genetic testing results and their implications for the patient's care plan.

Back to Table of Contents

References

1. Sliwa K, Fett J, Elkayam U. "Peripartum cardiomyopathy." Lancet. 2006;368(9536):687–693. PMID: 16920473
2. Pearson GD, Veille JC, Rahimtoola S, et al. "Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop recommendations and review." JAMA. 2000;283(9):1183–1188. PMID: 10703781
3. Sliwa K, Blauwet L, Tibazarwa K, et al. "Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study." Circulation. 2010;121(13):1465–1473. PMID: 20308616
4. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. "A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy." Cell. 2007;128(3):589–600. PMID: 17289576
5. McNamara DM, Elkayam U, Alharethi R, et al. "Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy)." J Am Coll Cardiol. 2015;66(8):905–914. PMID: 26293760
6. Ware JS, Li J, Mazaika E, et al. "Shared genetic predisposition in peripartum and dilated cardiomyopathies." N Engl J Med. 2016;374(3):233–241. PMID: 26735901
7. Hibbard JU, Lindheimer M, Lang RM. "A modified definition for peripartum cardiomyopathy and prognosis based on echocardiography." Obstet Gynecol. 1999;94(2):311–316. PMID: 10432107
8. Bauersachs J, König T, van der Meer P, et al. "Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy." Eur J Heart Fail. 2019;21(7):827–843. PMID: 31338916
9. Honigberg MC, Givertz MM. "Peripartum cardiomyopathy." BMJ. 2019;364:k5287. PMID: 30700460
10. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. "Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy." Circulation. 2010;121(20):2169–2175. PMID: 20458012
11. Arany Z, Elkayam U. "Peripartum cardiomyopathy." Circulation. 2016;133(14):1397–1409. PMID: 27045128
12. Sliwa K, Petrie MC, van der Meer P, et al. "Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the ESC Study Group on PPCM." Eur J Heart Fail. 2017;19(9):1131–1141. PMID: 28271625

Back to Table of Contents

Connections

• Dilated Cardiomyopathy
• Heart Failure
• Cardiomyopathy
• HELLP Syndrome
• Hypertrophic Cardiomyopathy
• Arrhythmogenic Cardiomyopathy
• Preeclampsia

Featured Videos